Treats chronic idiopathic constipation (CIC). ANDA 218492, held by Novitium Pharma. Prucalopride Succinate.
As of Nov 16, 2026, ANDA 218492 (Prucalopride Succinate), held by Novitium Pharma, was first approved by FDA on Dec 26, 2024, with 1 approved supplement and 0 published complete response letters.
Prucalopride tablet is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 26, 2024 | Original application | Approved |
| Prucalopride SuccinateEQ 1MG BASE · tablet;oral | Prucalopride Succinate | Rx |
| Prucalopride SuccinateEQ 2MG BASE · tablet;oral | Prucalopride Succinate | Rx |
| Nov 9, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 26, 2024 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters